Found 285 articles for: "biologics"
Meeting Patient Expectations of Topical Psoriasis Treatment: Evidence Supporting the Use of Fixed-Combination Halobetasol/Tazarotene Lotion
February 2023 | Volume 22 | Issue 2 | Original Article | 132 | Copyright © February 2023
Discordance between patient and clinician treatment goals and expectations can present a challenge to implementation of effective therapeutic plans. Because topical treatments are commonly used for pl...
Read MoreDifferential RNA Transcriptome in Ustekinumab Responders vs Non-Responders
February 2023 | Volume 22 | Issue 2 | Features | 219 | Copyright © February 2023
Despite numerous available psoriasis treatments, no "one size fits all" regimen provides complete disease control without side effects, logistical obstacles, and/or expense. Despite increasingly effic...
Read MoreSupplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations
January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3446174 | Copyright © January 2023
Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells. Understanding of the key pla...
Read MoreImprovement in Skin Elasticity Using Red Deer Umbilical Cord Lining Mesenchymal Stem Cell Conditioned Media
January 2023 | Volume 22 | Issue 1 | Original Article | 82 | Copyright © January 2023
Background: Significant improvement in skin tone was reported after topical application of a facial cream (CALECIM® Professional Multi-Action Cream, CALECIM Cosmeceutic...
Read MoreImmune-Response Modifiers: Characteristics of High-Volume Prescribers
December 2022 | Volume 21 | Issue 12 | Original Article | 1283 | Copyright © December 2022
Background: Oral small molecules (OSM) and biologic immune response modifier drugs share some indications for use but have a different side effect profiles. As such, certain providers...
Read MoreJAK Inhibitor Safety Compared to Traditional Systemic Immunosuppressive Therapies
December 2022 | Volume 21 | Issue 12 | Original Article | 1298 | Copyright © December 2022
Dermatologists treating atopic dermatitis are interested in the safety profile of the recently available JAK inhibitors, upadacitinib and abrocitinib, especially after they received boxed safety warni...
Read MoreNovel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report
December 2022 | Volume 21 | Issue 12 | Case Reports | 1358 | Copyright © December 2022
Hidradenitis suppurativa (HS) is a morbid, recurrent skin condition that presents a major challenge to clinical therapy. Investigation into the pathogenesis of HS has implicated local and systemic pro...
Read MoreEfficacy of a Fractionated 1540-nm Erbium Glass Laser in the Treatment of Dermatofibromas
November 2022 | Volume 21 | Issue 11 | Original Article | 1201 | Copyright © November 2022
Background: Treatment of dermatofibromas, beyond surgical excision, has remained inadequate and elusive. Nonsurgical treatment options are desired by both patients and physicians. Erb...
Read MoreEvolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care
October 2022 | Volume 21 | Issue 10 | Original Article | 1054 | Copyright © October 2022
Background: Despite considerable advances in our understanding of the pathogenesis and treatment of psoriasis, data pertaining to racial/ethnic variations, effects on barrier function...
Read MoreAnnual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019
October 2022 | Volume 21 | Issue 10 | Editorials | 1138 | Copyright © October 2022
Disease control for moderate to severe atopic dermatitis (AD) has been primarily achieved with phototherapy and non-specific immunomodulators, cyclosporine, and methotrexate. These treatments have, ho...
Read MoreDermal Safety of Tapinarof Cream 1%: Results From 4 Phase 1 Trials
October 2022 | Volume 21 | Issue 10 | Original Article | 1084 | Copyright © October 2022
Background: Tapinarof (VTAMA®; Dermavant Sciences, Inc.) is a novel, non-steroidal, topical, aryl hydrocarbon receptor agonist, FDA approved for psoriasis treatment and...
Read MorePersistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data
August 2022 | Volume 21 | Issue 8 | Original Article | 881 | Copyright © August 2022
Background: Psoriasis is a chronic, autoimmune-mediated inflammatory disorder. Drug persistence is a composite measure of effectiveness, safety, and treatment satisfaction, often esti...
Read MoreSevere Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment
August 2022 | Volume 21 | Issue 8 | Case Reports | 897 | Copyright © August 2022
Psoriasis, a chronic inflammatory skin condition, affects about 2% of children. A small subset have isolated nail involvement refractory to topical treatment that can be disabling. The development of ...
Read MoreUnmet Needs in Psoriasis Patients
August 2022 | Volume 21 | Issue 8 | Original Article | 839 | Copyright © August 2022
Background: Psoriasis can greatly impact patients' quality of life. The introduction of new treatments has improved treatment outcomes, but treatment gaps may still exist.
Read More The Incidence and Risk of Respiratory Tract Infections in Patients Using Biologics for Hidradenitis Suppurativa: A Systematic Review and Meta-analysis
August 2022 | Volume 21 | Issue 8 | Original Article | 819 | Copyright © August 2022
Background: Patients treated with biological therapy for hidradenitis suppurativa (HS) are at an increased risk of infectious complications. However, it is unclear whether these patie...
Read MoreNew Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 826 | Copyright © August 2022
Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and impro...
Read MoreOnset of Plaque Psoriasis Treatment Responses With Anti-IL-17/IL-23 Biologic Therapies
August 2022 | Volume 21 | Issue 8 | Original Article | 854 | Copyright © August 2022
Background: The impact of psoriasis on quality of life arises from both physical symptoms, such as pain and pruritus, and the psychosocial effects of the often highly visible lesions....
Read MoreTreatment of Scalp Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 833 | Copyright © August 2022
Scalp involvement is seen in a majority of individuals with psoriasis, a chronic autoimmune skin disease with variable phenotypes. Occasionally, isolated scalp involvement is observed; and this causes...
Read More"I'm Off My Meds": Public Perception of Interactions Between SARS-CoV-2 Vaccines and Anti-Psoriatic Treatments Online
August 2022 | Volume 21 | Issue 8 | Features | 901 | Copyright © August 2022
Importance: Psoriasis patients may seek information about the SARS-CoV-2 vaccine and their diagnosis from social media platforms. Analyses of social media interactions may help guide dermatologists&rs...
Read MoreSingle-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis
August 2022 | Volume 21 | Issue 8 | Original Article | 864 | Copyright © August 2022
The efficacy of guselkumab has been demonstrated in randomized controlled trials, but real-life data are still missing. This study presents a single-center real-life experience in treating moderate-to...
Read More